GlassScriptPhysician profile
Madison Dawn Odom
NPI 1851949416
$1,887.23
in general payments reported to CMS, 2019-2025
22 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $232 · 2023: $754 · 2024: $529 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,654.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $658.37 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $253.66 | 2022-2025 | |
| Pfizer INC. | $152.41 | 2023-2025 | |
| Lilly USA, LLC | $142.41 | 2022-2024 | Mounjaro, Zepbound |
| Intuitive Surgical, INC. | $136.46 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $105.80 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $80.81 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $65.21 | 2022-2025 | Evenity, Prolia, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.75 | 2023 | Xifaxan, Trulance |
| Exact Sciences Corporation | $35.82 | 2023-2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $26.31 | 2025 | Auvelity |
| Astellas Pharma US INC | $22.36 | 2023 | Veozah |
| Phathom Pharmaceuticals, INC. | $21.56 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $19.70 | 2024 | Rexulti |
| Corium, LLC | $18.78 | 2023 | Azstarys |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $18.25 | 2025 | Quviviq |
| Bausch Health US, LLC | $17.64 | 2022 | |
| Kaleo, INC. | $16.36 | 2022 | |
| Antares Pharma, INC. | $15.69 | 2024 | Xyosted |
| Merck Sharp & Dohme LLC | $14.77 | 2022 | |
| Sumitomo Pharma America, INC. | $13.57 | 2024 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Odom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.